FAQ: Oncotelic Therapeutics' Deciparticle™ Everolimus Presentations at 2025 San Antonio Breast Cancer Symposium

What is the main announcement from Oncotelic Therapeutics?

Oncotelic Therapeutics announced that three abstracts featuring its investigational intravenous Deciparticle™ everolimus (Sapu003) have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium. The abstracts detail clinical rationale, molecular biomarkers, and pharmacokinetic data supporting the ongoing Phase 1 trial.

What is Deciparticle™ everolimus (Sapu003) and how does it work?

Sapu003 is a novel intravenous formulation of everolimus designed to overcome limitations of oral mTOR inhibitors like Afinitor®, including poor bioavailability and restricted tumor penetration. It was developed by Sapu Nano, a joint venture between Oncotelic and Dragon Oversea, using nanomedicine technology.

When and where will these presentations take place?

The presentations will occur at the 2025 San Antonio Breast Cancer Symposium, which is scheduled to be held December 9-12, 2025, in San Antonio, Texas.

What type of cancer is Sapu003 being developed to treat?

Sapu003 is being developed for HR⁺/HER2⁻ metastatic breast cancer, with the ongoing Phase 1 trial focusing on this specific cancer subtype.

Why is this development significant for cancer treatment?

This development is significant because Sapu003 addresses key limitations of existing oral mTOR inhibitors like Afinitor® by improving bioavailability and tumor penetration through its novel intravenous formulation. This could potentially lead to better treatment outcomes for patients with metastatic breast cancer.

What is Oncotelic Therapeutics’ background and expertise?

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products. The company’s CEO, Dr. Vuong Trieu, has filed more than 150 patent applications and holds 39 issued U.S. patents, demonstrating strong expertise in drug development.

Where can I find more detailed information about this announcement?

The full press release is available at https://ibn.fm/Ut6V8, and the latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC.

What other business relationships does Oncotelic have?

Beyond its internal programs, Oncotelic licenses and codevelops drug candidates through joint ventures, including owning 45% of GMP Bio, a joint venture advancing its own pipeline of drug candidates that complement Oncotelic’s strategic position in oncology and rare disease therapeutics.